Browsing category:

Drug Research & Development API

LGM Helps Pharma Manage Supply Chain Risks with Added Services Through Nexgen Acquisition

COVID-19 has put supply chain risk management practices under the microscope. Coming on the heels of many other, more localized supply issues in the last decade, it has brought about a near-global assessment that supply chains need to be more tightly controlled and redundant – and less dependent on external, at-risk suppliers. In a sense,[…]

Read More

API Sourcing Challenges

Pharma and biopharmaceutical supply chains continue to grow more complex & global. The process of sourcing active pharmaceutical ingredients (APIs) and intermediates has also become more challenging. In 2018, ISR Reports looked at how experience and capacity impact small molecule API outsourcing. Among the findings, about 25% of respondents indicated their company lacked the capacity[…]

Read More

Naltrexone is typically administered to those who have a history of substance abuse, namely opiates or alcohol. The drug works to block the intensity of the drugs, so people are less likely to associate them with euphoria or pain relief. Because drug use in this country is still so stigmatized, it’s difficult to separate public[…]

Read More

Fingolimod Hydrochloride blog

Fingolimod Hydrochloride CAS: 162359-56-0 Fingolimod Hydrochloride is typically given to those who suffer from multiple sclerosis (MS) relapses. It doesn’t eliminate episodes in the body entirely, but it can reduce them by 50% or more over the course of several years. When the body is having an autoimmune reaction, the lymphocytes play a big role[…]

Read More

Amphotericin B

Amphotericin B: CAS No: 1397-89-3 Amphotericin B is an API used to treat a number of fungal infections. This pharmaceutical ingredient is aggressive when interacting with the fungus which is why it’s generally used for serious cases only. However, it’s also proven itself to be one of the most effective ways to stop the spread[…]

Read More

Sitagliptin Phosphate

Sitagliptin Phosphate CAS No: 654671-78-0 Sitagliptin Phosphate was approved more than a decade ago primarily as a way to combat type 2 diabetes. This dipeptidyl-peptidase-4 inhibitor lowers the levels of glucose in the patient directly following a meal and can also help regulate general blood sugar levels over time. It’s usually used in combination with[…]

Read More

Brimonidine Tartrate

Brimonidine Tartrate CAS No: 79570-19-7 Known for treating open-angle glaucoma, brimonidine tartrate is a safe and effective API for reducing pressure behind the eye. The medication allows better drainage of fluids to both relieve patient suffering and protect eyes from further damage. High-fluid pressure can cause anything from mild nerve damage to total blindness. However,[…]

Read More

Chemical entities SHINE in the top 10 fastest-growing drugs of 2016

This week, PharmaCompass continued its analysis of the top 10 fastest-growing drugs of 2016 by sales to evaluate the drugs that registered large sales growth. Please note that these are not the top-selling drugs, but are the top 10 drugs that registered the maximum growth in global sales over 2015. Interestingly, things didn’t appear that[…]

Read More

Eteplirsen CAS 1173755-55-9

The U.S. Food and Drug Administration approved Eteplirsen CAS# 1173755-55-9 (marketed as Exondys 51) injection, the first drug approved to treat patients with Duchenne muscular dystrophy (DMD). Exondys 51 is specifically indicated for patients who have a confirmed mutation of the dystrophin gene amenable to exon 51 skipping, which affects about 13 percent of the[…]

Read More

LGM Pharma Acquires CDMO

On July 27, 2020, LGM Pharma announced its acquisition of the formulation development and drug product contract manufacturing business of Nexgen Pharma, Inc. As a result, you will notice our new logo and visuals throughout the website. We’re working on updates to reflect the exciting, expanded CDMO capabilities and services we now can offer you.

This website uses cookies. By using our site, you agree to our terms of service